CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it presented pre-clinical data at the 2nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) held October 19-21, 2006 in New York City. Alnylam scientists presented pre-clinical in vivo efficacy data from its hypercholesterolemia program evaluating new approaches for reducing LDL-cholesterol levels using RNAi therapeutics directed to a disease target called proprotein convertase subtilisn/kexin type 9, or PCSK9. Alnylam is conducting this program in collaboration with researchers at University of Texas Southwestern Medical Center at Dallas with a focus on developing RNAi therapeutics for PCSK9, a key gene involved in the regulation of LDL cholesterol. An update on Alnylam’s microRNA (miRNA) effort was also presented at the meeting.
